MAPT and Alzheimer disease: Following the MDT evaluation, based on the results of the neuropsychological tests, the dosage of the levels of specific proteins (amyloid and tau) in the cerebrospinal fluid (CSF) if available, integration/comparison with morphological imaging (Magnetic Resonance Imaging), and evaluation of the evolution of the disease until last neurological evaluation (>24 months), 22/23 amyloid-PET positive patients were definitively classified as AD patients, while the remainder as non-AD.